幽门螺杆菌生物膜形成与其耐药机制的相关性

doi:10.3969/j.issn.1673-8640.2014.08.020

摘要/Abstract

摘要： 生物膜的形成是幽门螺杆菌引起消化道反复难治性感染的主要因素。本文主要从生物膜的组成结构、形成动力学以及细菌密度感应系统等3个方面探讨幽门螺杆菌生物膜的耐药机制,系统阐述了该研究方向现有的渗透与营养限制、对抗免疫防御系统、基因水平转移和外排泵基因异常表达等4种学说,并对幽门螺杆菌生物膜防治策略的研究进展做一综述。

关键词: 幽门螺杆菌, 生物膜, 耐药性, 相关性

Abstract: Biofilm formation plays an important role in gastrointestinal tract recurrent refractory infections caused by Helicobacter pylori. This review discusses the formation and structure, formation kinetics and quorum sensing system of Helicobacter pylori biofilm, in order to describe the recent advances in the research direction of its drug resistance mechanism. There includes 4 theories, osmosis and nutrient limitation, fighting against immune system, horizontal gene transfer and the anomaly expression of efflux pump genes. This review also summarizes the research progress of prevention strategies to Helicobacter pylori biofilm.

Key words: Biofilm, Drug resistance, Relationship

中图分类号:

R378.99

胡玢婕, 赵付菊, 赵虎. 幽门螺杆菌生物膜形成与其耐药机制的相关性[J]. 检验医学, 2014, 29(8): 865-870.

HU Binjie, ZHAO Fuju, ZHAO Hu. Study on the relationship between biofilm formation and drug resistance of Helicobacter pylori[J]. , 2014, 29(8): 865-870.

参考文献

[1] Yonezawa H, Osaki T, Kurata S, et al. Outer membrane vesicles of Helicobacter pylori TK1402 are involved in biofilm formation[J]. BMC Microbiol, 2009,9:197.
[2] Cammarota G, Sanguinetti M, Gallo A, et al. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection[J]. Aliment Pharmacol Ther, 2012,36(3):222-230.
[3] 陈波曼, 余加林. 细菌生物膜形成和耐药机制研究进展[J]. 中国抗生素杂志, 2005,30(10):S1-S4.
[4] Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases[J]. Nat Rev Microbiol, 2004,2(2):95-108.
[5] Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections[J]. Cell Microbiol, 2009,11(7):1034-1043.
[6] Høiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms[J]. Int J Antimicrob Agents, 2010,35(4):322-332.
[7] Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration[J]. Lancet, 1984,1(8390):1311-1315.
[8] Stark RM, Gerwig GJ, Pitman RS, et al. Biofilm formation by Helicobacter pylori [J]. Lett Appl Microbiol, 1999,28(2):121-126.
[9] Schooling SR, Beveridge TJ. Membrane vesicles: an overlooked component of the matrices of biofilms[J]. J Bacteriol, 2006,188(16):5945-5957.
[10] Yonezawa H, Osaki T, Woo T, et al. Analysis of outer membrane vesicle protein involved in biofilm formation of Helicobacter pylori [J]. Anaerobe, 2011,17(6):388-390.
[11] Yang FL, Hassanbhai AM, Chen HY, et al. Proteomannans in biofilm of Helicobacter pylori ATCC 43504[J]. Helicobacter, 2011,16(2):89-98.
[12] Grande R, Di Giulio M, Bessa LJ, et al. Extracellular DNA in Helicobacter pylori biofilm: a backstairs rumour[J]. J Appl Microbiol, 2011,110(2):490-498.
[13] Peng M, Ping Gong J, Osada Y. Substrate effect on the formation of hydrogels with heterogeneous network structure[J]. Chem Rec, 2003,3(1):40-50.
[14] Mattick JS. Type Ⅳ pili and twitching motility[J]. Annu Rev Microbiol, 2002,56:289-314.
[15] Yonezawa H, Osaki T, Kurata S, et al. Assessment of in vitro biofilm formation by Helicobacter pylori [J]. J Gastroenterol Hepatol, 2010,25 (Suppl 1): S90-S94.
[16] Jensen PØ, Bjarnsholt T, Phipps R, et al. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa [J]. Microbiology, 2007,153(Pt 5):1329-1338.
[17] Jayaraman A, Wood T K. Bacterial quorum sensing: signals, circuits, and implications for biofilms and disease[J]. Annu Rev Biomed Eng, 2008,10:145-167.
[18] 杨瑞宁, 操敏, 李先富, 等. 细菌中LuxS/AI-2密度感应系统分子机制研究进展[J]. 检验医学, 2013,28(9):856-861.
[19] Rader BA, Wreden C, Hicks KG, et al. Helicobacter pylori perceives the quorum-sensing molecule AI-2 as a chemorepellent via the chemoreceptor TlpB[J]. Microbiology, 2011,157(Pt 9):2445-2455.
[20] Cole SP, Harwood J, Lee R, et al. Characterization of monospecies biofilm formation by Helicobacter pylori [J]. J Bacteriol, 2004,186(10):3124-3132.
[21] Cellini L, Grande R, Di Campli E, et al. Dynamic colonization of Helicobacter pylori in human gastric mucosa[J]. Scand J Gastroenterol, 2008,43(2):178-185.
[22] Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht Ⅲ Consensus Report[J]. Gut, 2007,56(6):772-781.
[23] Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection[J]. Am J Gastroenterol, 2007,102(8):1808-1825.
[24] Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea[J]. Helicobacter, 2007,12(1):31-35.
[25] Lewis K. Multidrug tolerance of biofilms and persister cells[J]. Curr Top Microbiol Immunol, 2008,322:107-131.
[26] Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections[J]. Science, 1999,284(5418):1318-1322.
[27] Cole SP, Cirillo D, Kagnoff MF, et al. Coccoid and spiral Helicobacter pylori differ in their abilities to adhere to gastric epithelial cells and induce interleukin-8 secretion[J]. Infect Immun, 1997,65(2):843-846.
[28] Grande R, Di Campli E, Di Bartolomeo S, et al. Helicobacter pylori biofilm: a protective environment for bacterial recombination[J]. J Appl Microbiol, 2012,113(3):669-676.
[29] Ramsey MM, Whiteley M. Polymicrobial interactions stimulate resistance to host innate immunity through metabolite perception[J]. Proc Natl Acad Sci USA, 2009,106(5):1578-1583.
[30] Hirata K, Suzuki H, Nishizawa T, et al. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori [J]. J Gastroenterol Hepatol, 2010,25 (Suppl 1):S75-S79.
[31] Zuin R, Palamidese A, Negrin R, et al. High-dose-N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease[J]. Clin Drug Investig, 2005,25(6):401-408.
[32] Cammarota G, Branca G, Ardito F, et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori : a clinical trial[J]. Clin Gastroenterol Hepatol, 2010,8(9):817-820.
[33] Gurbuz AK, Ozel AM, Ozturk R, et al. Effect of N-acetyl cysteine on Helicobacter pylori [J]. South Med J, 2005,98(11):1095-1097.
[34] 刘伟, 于晗, 李玉瑭, 等. 二烯丙基三硫醚对幽门螺杆菌生物膜的杀菌作用[J]. 山东大学学报(医学版), 2013,51(10):49-53.
[35] 黄衍强, 黄干荣, 李晓华, 等. 中药提取物对耐药幽门螺杆菌生物膜形成的影响[J]. 医药导报, 2013,32(11):1407-1409.
[36] Di Campli E, Di Bartolomeo S, Grande R, et al. Effects of extremely low-frequency electromagnetic fields on Helicobacter pylori biofilm[J]. Curr Microbiol, 2010,60(6):412-418.
[37] Hongying F, Xianbo W, Fang Y, et al. Oral immunization with recombinant Lactobacillus acidophilus expressing the adhesin Hp0410 of Helicobacter pylori induces mucosal and systemic immune responses[J]. Clin Vaccine Immunol, 2014,21(2):126-132.